8-K: Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce SEC Effectiveness for Business Combination

Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics announced that their Registration Statement on Form S-4 for their proposed business combination has been declared effective by the SEC, paving the way for a shareholder vote and anticipated August 2025 closing.

Summary

• Helix Acquisition Corp. II (HLXB) and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) (BBOT) jointly announced that their Registration Statement on Form S-4 has been declared effective by the U.S. Securities and Exchange Commission (SEC) on July 10, 2025.
• This effectiveness is a key procedural step towards the previously announced business combination between Helix and BBOT.
• An Extraordinary General Meeting of Helix shareholders is scheduled for August 4, 2025, to vote on the Business Combination.
• The definitive Proxy Statement/Prospectus will be mailed to Helix's shareholders of record as of June 30, 2025.
• The parties anticipate the Business Combination will close in August 2025, subject to satisfaction of closing conditions.
• Upon closing of the transaction, the combined company will be renamed BridgeBio Oncology Therapeutics (PubCo).

Sentiment

Score: 7

Explanation: The declaration of effectiveness for the S-4 registration statement is a significant positive procedural milestone for the business combination, indicating progress towards completion. While it doesn't provide new financial performance data, it removes a key regulatory hurdle.

Positives

• The Registration Statement on Form S-4 for the business combination has been declared effective by the SEC, a critical regulatory milestone.
• An Extraordinary General Meeting of Helix shareholders has been scheduled for August 4, 2025, indicating clear progress towards the merger.
• The business combination is anticipated to close in August 2025, providing a clear timeline for the transaction's completion.
• BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company with a pipeline targeting prevalent oncogenes (RAS and PI3K malignancies), indicating potential for future growth.

Risks

• Changes in domestic and foreign business, market, financial, political, and legal conditions.
• Inability of parties to successfully or timely enter into definitive agreements or consummate the business combination.
• Risk that regulatory approvals are not obtained, are delayed, or are subject to unanticipated conditions, including SEC statements or enforcements relating to SPACs.
• Risk that the approval of Helix shareholders or any other condition to closing is not obtained.
• Failure to realize the anticipated benefits of the business combination.
• Risks relating to any legal proceedings that may be instituted against Helix, the combined company, or others following the announcement of the business combination.
• Uncertainty of the projected financial information with respect to BBOT and the combined company.
• Risks related to the approval of BBOT's product candidates and the timing of expected regulatory and business milestones.
• Ability to negotiate definitive contractual arrangements with potential customers.
• Impact of competitive product candidates.
• Ability to obtain sufficient supply of materials.
• Global economic and political conditions.
• Effects of competition on BBOT's future business.
• Amount of redemption requests made by Helix's public shareholders.
• Uncertainty regarding outcomes of BBOT's ongoing clinical trials, particularly as they relate to regulatory review and potential approval for its product candidates.
• Risks associated with BBOT's efforts to commercialize its product candidates.
• BBOT's ability to maintain its existing agreements with third parties and to negotiate and enter into new definitive agreements on favorable terms.
• Intellectual property-related claims.
• BBOT's ability to attract and retain qualified personnel.
• BBOT's ability to source the raw materials for its product candidates.
• Existence of additional unknown or currently immaterial risks that could cause actual results to differ.

Future Outlook

The business combination between Helix and BBOT is anticipated to close in August 2025, subject to shareholder approval and other closing conditions. The combined entity, BridgeBio Oncology Therapeutics (PubCo), aims to advance a pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies, with ongoing clinical trials for ONKORAS-101 and BREAKER-101, and expected dosing of the first patient with BBO-11818. Management anticipates the clinical and therapeutic potential of BBO-8520, BBO-10203, and BBO-11818, along with growth in the markets for BBOT's product candidates, and expects to realize the benefits of the business combination, including proceeds and an extended cash runway.

Management Comments

• Management expects the business combination to close in August 2025.
• Management anticipates the clinical and therapeutic potential of BBOT's product candidates, including BBO-8520, BBO-10203, and BBO-11818.
• Management expects progress and results from the ONKORAS-101 and BREAKER-101 clinical trials and the dosing of the first patient with BBO-11818.
• Management anticipates the combined company will have an expected cash runway following the business combination and financing.

Industry Context

This announcement is a typical procedural step in the SPAC (Special Purpose Acquisition Company) merger process, where a SPAC (Helix) combines with a private operating company (BBOT) to take it public. In the biopharmaceutical sector, such combinations are common for clinical-stage companies like BBOT, which are developing novel therapeutics for significant medical needs, in this case, cancers driven by RAS and PI3K oncogenes. The effectiveness of the S-4 registration statement is a crucial regulatory hurdle cleared, indicating progress towards the public listing of a new oncology-focused biotech entity.

Legal Proceedings

• The document mentions a risk of "any legal proceedings that may be instituted against Helix, the combined company or others following the announcement of the business combination," but does not disclose any current or active legal proceedings.

Stakeholder Impact

• Shareholders: Helix shareholders will vote on the business combination and, if approved, will become shareholders of the combined entity (PubCo). The amount of redemption requests by Helix's public shareholders is a risk factor.
• Employees: The business combination will create a combined entity, potentially impacting employees of both Helix and BBOT. BBOT's ability to attract and retain qualified personnel is noted as a risk.
• Customers/Patients: The combined company, BridgeBio Oncology Therapeutics, aims to develop novel therapeutics for patients with cancers, potentially improving outcomes for those with RAS and PI3K malignancies.
• Suppliers: BBOT's ability to source raw materials for its product candidates is identified as a risk.
• Creditors: The financial health and future operations of the combined entity could impact creditors.

Next Steps

• Mailing of the definitive Proxy Statement/Prospectus to Helix's shareholders of record as of June 30, 2025.
• Extraordinary General Meeting of Helix shareholders on August 4, 2025, to vote on the Business Combination.
• Anticipated closing of the Business Combination in August 2025, subject to satisfaction or waiver of conditions.
• Upon closing, the company will be renamed BridgeBio Oncology Therapeutics (PubCo).
• Continued progress and results of BBOT's ONKORAS-101 and BREAKER-101 clinical trials.
• Expected dosing of the first patient with BBO-11818.

Key Dates

Recommendation

Keywords

SPAC, Business Combination, Biopharmaceutical, Oncology, RAS, PI3K, Clinical-stage, SEC Filing, Form S-4, Merger, HLXB, BBOT, BridgeBio Oncology Therapeutics, Cormorant Asset Management